Key result
Longer PVARP and atrial pacing delays offer superior arrhythmia protection, with Abbott uniquely terminating PMT.
Why the study?
The behavior of device-specific anti-pacemaker-mediated tachycardia (PMT) algorithms and the potential utility of DDI mode in scenarios with prolonged ventriculoatrial conduction remained to be fully elucidated.
How do device-specific anti-PMT algorithms perform in detecting and terminating pacemaker-mediated tachycardia during prolonged ventriculoatrial conduction?
How do device-specific anti-PMT algorithms perform in detecting and terminating pacemaker-mediated tachycardia during prolonged ventriculoatrial conduction?
Anti-PMT performance varies markedly among manufacturers during prolonged ventriculoatrial conduction, highlighting the need for individualized pacemaker selection and programming.
Highlights critical vendor-specific vulnerabilities in PMT detection during prolonged VAC; leaves open how these simulator.
Background Pacemaker‐mediated tachycardia (PMT) triggered by prolonged ventriculoatrial conduction (VAC) can be challenging to detect and terminate. The behavior of device‐specific anti‐PMT algorithms in such scenarios, as well as the potential utility of DDI mode as an alternative strategy, remain to be fully elucidated. Methods Five dual‐chamber pacemakers from Abbott, BIOTRONIK, Boston Scientific, Medtronic, and MicroPort CRM were tested using an electrophysiological simulator under VAC times of 450 ms and 550 ms. We assessed (1) PMT detection and termination in DDD mode, (2) atrial sensing within the post‐ventricular atrial refractory period (PVARP) in DDI mode, and (3) the timing adjustment of atrial pacing after retrograde atrial sensing. Results At VAC 450 ms, all devices except Medtronic detected PMT. Only Abbott terminated PMT at 550 ms with a shortened AV delay. Four devices detected atrial events within PVARP at 450 ms, whereas only BIOTRONIK did so at 550 ms. Among these, BIOTRONIK, Boston Scientific, and Medtronic adapted atrial pacing timing following atrial sensing within the refractory period, while Abbott did not, resulting in repetitive nonreentrant ventriculoatrial synchrony. Conclusions Anti‐PMT performance varies markedly among manufacturers. Devices featuring a longer PVARP and an atrial pacing delay algorithm provide superior protection against pacemaker‐mediated arrhythmias during prolonged VAC. These findings underscore the importance of individualized pacemaker selection and careful programming.
No takes yet. Share an insight, caveat, or question.
Tsunomori et al. (2026) studied this question. Pacemakers with longer PVARP and atrial pacing delay algorithms offer superior protection against arrhythmias, though only Abbott successfully terminated PMT at 550 ms VAC.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: